Wojewódzki Szpital Specjalistyczny w Bialej Podlaskiej
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Centkowski, Piotr
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
01/25
05/26
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
02/25
08/28
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Recruiting
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
10/24
11/25
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe, Canada
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
POTAMI-61, NCT06397313: RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
JASPIS-01, NCT06534437: MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Not yet recruiting
2
178
Europe
MEN1703, SEL24, Glofitamab
Ryvu Therapeutics SA, Menarini Group
Non-Hodgkin Lymphoma, B-cell
12/26
12/26
2018-523-00US1, NCT03779113: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Active, not recruiting
1
140
Europe, US
HMPL-523
Hutchmed
Non Hodgkin Lymphoma
12/24
01/26

Download Options